19 results on '"Holley, Rebecca J."'
Search Results
2. Generation of a novel immunodeficient mouse model of Mucopolysaccharidosis type IIIA to test human stem cell-based therapies
- Author
-
Mandolfo, Oriana, Parker, Helen, Usman, Asma'u, Learmonth, Yuko Ishikawa, Holley, Rebecca J., MacDonald, Andrew, McKay, Tristan, and Bigger, Brian
- Published
- 2024
- Full Text
- View/download PDF
3. Establishment of the Effectiveness of Early Versus Late Stem Cell Gene Therapy in Mucopolysaccharidosis II for Treating Central Versus Peripheral Disease.
- Author
-
Mandolfo, Oriana, Liao, Aiyin, Singh, Esha, O'leary, Claire, Holley, Rebecca J., and Bigger, Brian W.
- Published
- 2024
- Full Text
- View/download PDF
4. Haematopoietic stem cell gene therapy with IL‐1Ra rescues cognitive loss in mucopolysaccharidosis IIIA.
- Author
-
Parker, Helen, Ellison, Stuart M, Holley, Rebecca J, O'Leary, Claire, Liao, Aiyin, Asadi, Jalal, Glover, Emily, Ghosh, Arunabha, Jones, Simon, Wilkinson, Fiona L, Brough, David, Pinteaux, Emmanuel, Boutin, Hervé, and Bigger, Brian W
- Abstract
Mucopolysaccharidosis IIIA is a neuronopathic lysosomal storage disease, characterised by heparan sulphate and other substrates accumulating in the brain. Patients develop behavioural disturbances and cognitive decline, a possible consequence of neuroinflammation and abnormal substrate accumulation. Interleukin (IL)‐1β and interleukin‐1 receptor antagonist (IL‐1Ra) expression were significantly increased in both murine models and human MPSIII patients. We identified pathogenic mechanisms of inflammasome activation, including that disease‐specific 2‐O‐sulphated heparan sulphate was essential for priming an IL‐1β response via the Toll‐like receptor 4 complex. However, mucopolysaccharidosis IIIA primary and secondary storage substrates, such as amyloid beta, were both required to activate the NLRP3 inflammasome and initiate IL‐1β secretion. IL‐1 blockade in mucopolysaccharidosis IIIA mice using IL‐1 receptor type 1 knockout or haematopoietic stem cell gene therapy over‐expressing IL‐1Ra reduced gliosis and completely prevented behavioural phenotypes. In conclusion, we demonstrate that IL‐1 drives neuroinflammation, behavioural abnormality and cognitive decline in mucopolysaccharidosis IIIA, highlighting haematopoietic stem cell gene therapy treatment with IL‐1Ra as a potential neuronopathic lysosomal disease treatment. Synopsis: This study reports that IL‐1, stimulated by storage substrates, is a critical mediator in the mucopolysaccharidosis IIIA (MPSIIIA) inflammatory cascade. Haematopoietic stem cell gene therapy using IL‐1Ra, the natural antagonist of IL‐1, prevented cognitive and behavioural decline in mice. IL‐1 blockade in MPSIIIA mice via lentiviral dependent haematopoietic stem cell overexpression of IL‐1Ra corrected cognitive decline and reduced neuroinflammation.2‐O‐sulphation of MPSIIIA heparan sulphate elicited production of TLR4 dependent IL‐1β.MPSIIIA primary and secondary storage substrates activated the inflammasome and induced secretion of IL‐1β.IL‐1β and IL‐1Ra are important immuno‐biomarkers in MPSIIIA patients and mice. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
5. An Improved Adeno-Associated Virus Vector for Neurological Correction of the Mouse Model of Mucopolysaccharidosis IIIA.
- Author
-
Gray, Anna L., O'Leary, Claire, Liao, Aiyin, Agúndez, Leticia, Youshani, Amir S., Gleitz, Hélène F., Parker, Helen, Taylor, Jessica T., Danos, Olivier, Hocquemiller, Michaël, Palomar, Nuria, Linden, R. Michael, Henckaerts, Els, Holley, Rebecca J., and Bigger, Brian W.
- Published
- 2019
- Full Text
- View/download PDF
6. Brain‐targeted stem cell gene therapy corrects mucopolysaccharidosis type II via multiple mechanisms.
- Author
-
Gleitz, Hélène F. E., Liao, Ai Yin, Cook, James R., Rowlston, Samuel F., Forte, Gabriella M. A., D'Souza, Zelpha, O'Leary, Claire, Holley, Rebecca J., and Bigger, Brian W.
- Abstract
Abstract: The pediatric lysosomal storage disorder mucopolysaccharidosis type II is caused by mutations in IDS, resulting in accumulation of heparan and dermatan sulfate, causing severe neurodegeneration, skeletal disease, and cardiorespiratory disease. Most patients manifest with cognitive symptoms, which cannot be treated with enzyme replacement therapy, as native IDS does not cross the blood–brain barrier. We tested a brain‐targeted hematopoietic stem cell gene therapy approach using lentiviral IDS fused to ApoEII (IDS.ApoEII) compared to a lentivirus expressing normal IDS or a normal bone marrow transplant. In mucopolysaccharidosis II mice, all treatments corrected peripheral disease, but only IDS.ApoEII mediated complete normalization of brain pathology and behavior, providing significantly enhanced correction compared to IDS. A normal bone marrow transplant achieved no brain correction. Whilst corrected macrophages traffic to the brain, secreting IDS/IDS.ApoEII enzyme for cross‐correction, IDS.ApoEII was additionally more active in plasma and was taken up and transcytosed across brain endothelia significantly better than IDS via both heparan sulfate/ApoE‐dependent receptors and mannose‐6‐phosphate receptors. Brain‐targeted hematopoietic stem cell gene therapy provides a promising therapy for MPS II patients. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
7. A novel adeno-associated virus capsid with enhanced neurotropism corrects a lysosomal transmembrane enzyme deficiency.
- Author
-
Tordo, Julie, O'Leary, Claire, Antunes, André S. L. M., Palomar, Nuria, Aldrin-Kirk, Patrick, Basche, Mark, Bennett, Antonette, D'Souza, Zelpha, Gleitz, Hélène, Godwin, Annie, Holley, Rebecca J., Parker, Helen, Ai Yin Liao, Rouse, Paul, Youshani, Amir Saam, Dridi, Larbi, Martins, Carla, Levade, Thierry, Stacey, Kevin B., and Davis, Daniel M.
- Subjects
LYSOSOMAL storage diseases ,NEUROLOGICAL disorders ,THERAPEUTICS ,MEMBRANE proteins ,ADENO-associated virus ,PHOTORECEPTORS ,MUCOPOLYSACCHARIDOSIS ,AMINO acids ,ANIMAL experimentation ,CELLULAR signal transduction ,GENE therapy ,GLYCOPROTEINS ,MICE ,VIRUSES - Abstract
Recombinant adeno-associated viruses (AAVs) are popular in vivo gene transfer vehicles. However, vector doses needed to achieve therapeutic effect are high and some target tissues in the central nervous system remain difficult to transduce. Gene therapy trials using AAV for the treatment of neurological disorders have seldom led to demonstrated clinical efficacy. Important contributing factors are low transduction rates and inefficient distribution of the vector. To overcome these hurdles, a variety of capsid engineering methods have been utilized to generate capsids with improved transduction properties. Here we describe an alternative approach to capsid engineering, which draws on the natural evolution of the virus and aims to yield capsids that are better suited to infect human tissues. We generated an AAV capsid to include amino acids that are conserved among natural AAV2 isolates and tested its biodistribution properties in mice and rats. Intriguingly, this novel variant, AAV-TT, demonstrates strong neurotropism in rodents and displays significantly improved distribution throughout the central nervous system as compared to AAV2. Additionally, sub-retinal injections in mice revealed markedly enhanced transduction of photoreceptor cells when compared to AAV2. Importantly, AAV-TT exceeds the distribution abilities of benchmark neurotropic serotypes AAV9 and AAVrh10 in the central nervous system of mice, and is the only virus, when administered at low dose, that is able to correct the neurological phenotype in a mouse model of mucopolysaccharidosis IIIC, a transmembrane enzyme lysosomal storage disease, which requires delivery to every cell for biochemical correction. These data represent unprecedented correction of a lysosomal transmembrane enzyme deficiency in mice and suggest that AAV-TT-based gene therapies may be suitable for treatment of human neurological diseases such as mucopolysaccharidosis IIIC, which is characterized by global neuropathology. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
8. Macrophage enzyme and reduced inflammation drive brain correction of mucopolysaccharidosis IIIB by stem cell gene therapy.
- Author
-
Holley, Rebecca J., Ellison, Stuart M., Fil, Daniel, O'Leary, Claire, McDermott, John, Senthivel, Nishanthi, Langford-Smith, Alexander W. W., Wilkinson, Fiona L., D'Souza, Zelpha, Parker, Helen, Liao, Aiyin, Rowlston, Samuel, Gleitz, Hélène F. E., Kan, Shih-Hsin, Dickson, Patricia I., and Bigger, Brian W.
- Subjects
- *
GENE therapy , *INFLAMMATION , *STEM cells , *GLYCOSAMINOGLYCANS , *THERAPEUTIC use of enzymes , *MUCOPOLYSACCHARIDOSIS treatment , *ANIMAL experimentation , *ANTI-inflammatory agents , *HEMATOPOIETIC stem cells , *LYSOSOMAL storage diseases , *MACROPHAGES , *MICE , *NERVOUS system , *CHONDROITIN , *CONNECTIVE tissue growth factor , *IN vivo studies - Abstract
Mucopolysaccharidosis IIIB is a paediatric lysosomal storage disease caused by deficiency of the enzyme α-N-acetylglucosaminidase (NAGLU), involved in the degradation of the glycosaminoglycan heparan sulphate. Absence of NAGLU leads to accumulation of partially degraded heparan sulphate within lysosomes and the extracellular matrix, giving rise to severe CNS degeneration with progressive cognitive impairment and behavioural problems. There are no therapies. Haematopoietic stem cell transplant shows great efficacy in the related disease mucopolysaccharidosis I, where donor-derived monocytes can transmigrate into the brain following bone marrow engraftment, secrete the missing enzyme and cross-correct neighbouring cells. However, little neurological correction is achieved in patients with mucopolysaccharidosis IIIB. We have therefore developed an ex vivo haematopoietic stem cell gene therapy approach in a mouse model of mucopolysaccharidosis IIIB, using a high-titre lentiviral vector and the myeloid-specific CD11b promoter, driving the expression of NAGLU (LV.NAGLU). To understand the mechanism of correction we also compared this with a poorly secreted version of NAGLU containing a C-terminal fusion to IGFII (LV.NAGLU-IGFII). Mucopolysaccharidosis IIIB haematopoietic stem cells were transduced with vector, transplanted into myeloablated mucopolysaccharidosis IIIB mice and compared at 8 months of age with mice receiving a wild-type transplant. As the disease is characterized by increased inflammation, we also tested the anti-inflammatory steroidal agent prednisolone alone, or in combination with LV.NAGLU, to understand the importance of inflammation on behaviour. NAGLU enzyme was substantially increased in the brain of LV.NAGLU and LV.NAGLU-IGFII-treated mice, with little expression in wild-type bone marrow transplanted mice. LV.NAGLU treatment led to behavioural correction, normalization of heparan sulphate and sulphation patterning, reduced inflammatory cytokine expression and correction of astrocytosis, microgliosis and lysosomal compartment size throughout the brain. The addition of prednisolone improved inflammatory aspects further. Substantial correction of lysosomal storage in neurons and astrocytes was also achieved in LV.NAGLU-IGFII-treated mice, despite limited enzyme secretion from engrafted macrophages in the brain. Interestingly both wild-type bone marrow transplant and prednisolone treatment alone corrected behaviour, despite having little effect on brain neuropathology. This was attributed to a decrease in peripheral inflammatory cytokines. Here we show significant neurological disease correction is achieved using haematopoietic stem cell gene therapy, suggesting this therapy alone or in combination with anti-inflammatories may improve neurological function in patients. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
9. Identification of age-dependent motor and neuropsychological behavioural abnormalities in a mouse model of Mucopolysaccharidosis Type II.
- Author
-
Gleitz, Hélène F. E., O’Leary, Claire, Holley, Rebecca J., and Bigger, Brian W.
- Subjects
MUCOPOLYSACCHARIDOSIS II ,NEUROPSYCHOLOGY ,MOVEMENT disorders ,BEHAVIOR disorders ,LABORATORY mice ,GENETIC mutation - Abstract
Severe mucopolysaccharidosis type II (MPS II) is a progressive lysosomal storage disease caused by mutations in the IDS gene, leading to a deficiency in the iduronate-2-sulfatase enzyme that is involved in heparan sulphate and dermatan sulphate catabolism. In constitutive form, MPS II is a multi-system disease characterised by progressive neurocognitive decline, severe skeletal abnormalities and hepatosplenomegaly. Although enzyme replacement therapy has been approved for treatment of peripheral organs, no therapy effectively treats the cognitive symptoms of the disease and novel therapies are in development to remediate this. Therapeutic efficacy and subsequent validation can be assessed using a variety of outcome measures that are translatable to clinical practice, such as behavioural measures. We sought to consolidate current knowledge of the cognitive, skeletal and motor abnormalities present in the MPS II mouse model by performing time course behavioural examinations of working memory, anxiety, activity levels, sociability and coordination and balance, up to 8 months of age. Cognitive decline associated with alterations in spatial working memory is detectable at 8 months of age in MPS II mice using spontaneous alternation, together with an altered response to novel environments and anxiolytic behaviour in the open-field. Coordination and balance on the accelerating rotarod were also significantly worse at 8 months, and may be associated with skeletal changes seen in MPS II mice. We demonstrate that the progressive nature of MPS II disease is also seen in the mouse model, and that cognitive and motor differences are detectable at 8 months of age using spontaneous alternation, the accelerating rotarod and the open-field tests. This study establishes neurological, motor and skeletal measures for use in pre-clinical studies to develop therapeutic approaches in MPS II. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
10. Delivering Hematopoietic Stem Cell Gene Therapy Treatments for Neurological Lysosomal Diseases.
- Author
-
Holley, Rebecca J., Wood, Shaun R., and Bigger, Brian W.
- Published
- 2019
- Full Text
- View/download PDF
11. Heparan Sulfate Inhibits Hematopoietic Stem and Progenitor Cell Migration and Engraftment in Mucopolysaccharidosis I.
- Author
-
Watson, H. Angharad, Holley, Rebecca J., Langford-Smith, Kia J., Wilkinson, Fiona L., van Kuppevelt, Toin H., Wynn, Robert F., Wraith, J. Edmond, Merry, Catherine L. R., and Bigger, Brian W.
- Subjects
- *
HEPARAN sulfate , *HEMATOPOIETIC stem cells , *PROGENITOR cells , *STEM cell migration , *MUCOPOLYSACCHARIDOSIS I - Abstract
Mucopolysaccharidosis I Hurler (MPSI-H) is a pediatric lysosomal storage disease caused by genetic deficiencies in IDUA, coding for alpha-L-iduronidase. Idua-/- mice share similar clinical pathology with patients, including the accumulation of the undegraded glycosaminoglycans (GAGs) heparan sulfate (HS) and dermatan sulphate (DS), progressive neurodegeneration and dysostosis multiplex. Hematopoietic stem cell transplantation (HSCT) is the most effective treatment for Hurler patients, but reduced intensity conditioning is a risk factor in transplantation, suggesting an underlying defect in hematopoietic cell engraftment. HS is a co-receptor in the CXCL12/CXCR4 axis of hematopoietic stem and progenitor cell (HSPC) migration to the bone marrow (BM), but the effect of HS alterations on HSPC migration, or the functional role of HS in MPSI-H are unknown. We demonstrate defective WT HSPC engraftment and migration in Idua-/- recipient BM, particularly under reduced intensity conditioning. Both intra- but especially extra-cellular Idua-/- BM HS was significantly increased and abnormally sulfated. Soluble heparinase-sensitive GAGs from Idua-/- BM and specifically 2-O-sulfated HS, elevated in Idua-/- BM, both inhibited CXCL12-mediated WT HSPC transwell migration, whilst DS had no effect. Thus we have shown that excess overly sulfated extracellular HS binds and sequesters CXCL12, limiting hematopoietic migration and providing a potential mechanism for the limited scope of HSCT in Hurler disease. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
12. Using embryonic stem cells to understand how glycosaminoglycans regulate differentiation.
- Author
-
Holley, Rebecca J., Meade, Kate A., and Merry, Catherine L. R.
- Subjects
- *
EMBRYONIC stem cells , *GLYCOSAMINOGLYCANS , *CELL differentiation , *CELLULAR signal transduction , *HEPARAN sulfate - Abstract
Differentiation and subsequent specialization of every cell within an organism is an intricate interwoven process. A complex network of signalling pathways eventually leads to the specification of a multitude of different cell types able to function co-operatively. HS (heparan sulfate) is a highly sulfated linear polysaccharide that resides at the pericellular cell-matrix interface where it dictates the binding and activity of a large number of proteins, including growth factors and morphogens such as members of the FGF (fibroblast growth factor) and BMP (bone morphogenetic protein) families. Embryonic stem cells derived from mice with mutations in components of the HS biosynthetic pathway provide an opportunity to dissect the contribution of HS to signalling pathways critical for regulating stem cell maintenance and differentiation. In addition to improving our understanding of signalling mechanisms, this knowledge enables the selection of exogenous HS saccharides to improve the efficiency and selectivity of directed differentiation protocols, offering a cost-effective alternative to high concentrations of expensive growth factors to drive differentiation towards a particular therapeutically relevant cell type. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
13. Neuropathology in Mouse Models of Mucopolysaccharidosis Type I, IIIA and IIIB.
- Author
-
Wilkinson, Fiona L., Holley, Rebecca J., Langford-Smith, Kia J., Badrinath, Soumya, Liao, Aiyin, Langford-Smith, Alex, Cooper, Jonathan D., Jones, Simon A., Wraith, J. Ed, Wynn, Rob F., Merry, Catherine L. R., and Bigger, Brian W.
- Subjects
- *
MUCOPOLYSACCHARIDOSIS , *NEUROLOGICAL disorders , *MUCOPOLYSACCHARIDES , *CARBOHYDRATE metabolism disorders , *COGNITION disorders - Abstract
Mucopolysaccharide diseases (MPS) are caused by deficiency of glycosaminoglycan (GAG) degrading enzymes, leading to GAG accumulation. Neurodegenerative MPS diseases exhibit cognitive decline, behavioural problems and shortened lifespan. We have characterised neuropathological changes in mouse models of MPSI, IIIA and IIIB to provide a better understanding of these events. Wild-type (WT), MPSI, IIIA and IIIB mouse brains were analysed at 4 and 9 months of age. Quantitative immunohistochemistry showed significantly increased lysosomal compartment, GM2 ganglioside storage, neuroinflammation, decreased and mislocalised synaptic vesicle associated membrane protein, (VAMP2), and decreased post-synaptic protein, Homer-1, in layers II/III-VI of the primary motor, somatosensory and parietal cortex. Total heparan sulphate (HS), was significantly elevated, and abnormally N-, 6-O and 2-O sulphated compared to WT, potentially altering HS-dependent cellular functions. Neuroinflammation was confirmed by significantly increased MCP-1, MIP-1a, IL-1a, using cytometric bead arrays. An overall genotype effect was seen in all parameters tested except for synaptophysin staining, neuronal cell number and cortical thickness which were not significantly different from WT. MPSIIIA and IIIB showed significantly more pronounced pathology than MPSI in lysosomal storage, astrocytosis, microgliosis and the percentage of 2-O sulphation of HS. We also observed significant time progression of all genotypes from 4-9 months in lysosomal storage, astrocytosis, microgliosis and synaptic disorganisation but not GM2 gangliosidosis. Individual genotype*time differences were disparate, with significant progression from 4 to 9 months only seen for MPSIIIB with lysosomal storage, MPSI with astrocytocis and MPSIIIA with microgliosis as well as neuronal loss. Transmission electron microscopy of MPS brains revealed dystrophic axons, axonal storage, and extensive lipid and lysosomal storage. These data lend novel insight to MPS neuropathology, suggesting that MPSIIIA and IIIB have more pronounced neuropathology than MPSI, yet all are still progressive, at least in some aspects of neuropathology, from 4-9 months. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
14. Mucopolysaccharidosis Type I, Unique Structure of Accumulated Heparan Sulfate and Increased N-Sulfotransferase Activity in Mice Lacking α-L-iduronidase.
- Author
-
Holley, Rebecca J., Deligny, Audrey, Wei Wei, Watson, H. Angharad, Niñonuevo, Milady R., Dagälv, Anders, Leary, Julie A., Bigger, Brian W., Kjellén, Lena, and Merry, Catherine L. R.
- Subjects
- *
MUCOPOLYSACCHARIDOSIS , *GLYCOSAMINOGLYCANS , *CELLULAR control mechanisms , *DISACCHARIDES , *LABORATORY mice - Abstract
Mucopolysaccharide (MPS) diseases are characterized by accumulation of glycosaminoglycans (GAGs) due to deficiencies in lysosomal enzymes responsible for GAG breakdown. Using a murine model of MPSI Hurler (MPSIH), we have quantified the heparan sulfate (HS) accumulation resulting from α-l-iduronidase (Idua) deficiency. HS levels were significantly increased in liver and brain tissue from 12-week-old Idua-/- mice by 87- and 20-fold, respectively. In addition, HS chains were shown to contain significantly increased N-, 2-O-, and 6-O-sulfation. Disaccharide compositional analyses also uncovered an HS disaccharide uniquely enriched in MPSIH, representing the terminal iduronic acid residue capping the non-reducing end of the HS chain, where no further degradation can occur in the absence of Idua. Critically, we identified that excess HS, some of which is colocalized to the Golgi secretory pathway, acts as a positive regulator of HS-sulfation, increasing the N-sulfotransferase activity of HS-modifying N-deacetylase/N-sulfotransferase enzymes. This mechanism may have severe implications during disease progression but, now identified, could help direct improved therapeutic strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
15. Specific Glycosaminoglycans Modulate Neural Specification of Mouse Embryonic Stem Cells.
- Author
-
PICKFORD, CLAIRE E., HOLLEY, REBECCA J., RUSHTON, GRAHAM, STAVRIDIS, MARIOS P., WARD, CHRISTOPHER M., and MERRY, CATHERINE L. R.
- Subjects
GLYCOSAMINOGLYCANS ,EMBRYONIC stem cells ,SULFATES ,CELLULAR signal transduction ,LABORATORY mice - Abstract
Mouse embryonic stem (mES) cells express a low sulfated form of heparan sulfate (HS). HS chains displayed by ES cells and their progeny become more complex and more sulfated during progression from pluripotency to neuroectodermal precursors. Sulfated epitopes are important for recognition and binding of a variety of ligands including members of the fibroblast growth factor (FGF) family. We demonstrated previously that mES cells lacking HS cannot undergo neural specification but this activity can be recovered by adding soluble heparin, a highly sulfated glycosaminoglycan (GAG). Therefore, we hypothesized that soluble GAGs might be used to support neural differentiation of HS competent cells and that the mechanisms underlying this activity might provide useful information about the signaling pathways critical for loss of pluripotency and early lineage commitment. In this study, we demonstrate that specific HS/heparin polysaccharides support formation of Sox1 neural progenitor cells from wild-type ES cells. This effect is dependent on sulfation pattern, concentration, and length of saccharide. Using a selective inhibitor of FGF signal transduction, we show that heparin modulates signaling events regulating exit from pluripotency and commitment to primitive ectoderm and subsequently neuroectoderm. Interestingly, we were also able to demonstrate that multiple receptor tyrosine kinases were influenced by HS in this system. This suggests roles for additional factors, possibly in cell proliferation or protection from apoptosis, during the process of neural specification. Therefore, we conclude that soluble GAGs or synthetic mimics could be considered as suitable low-cost factors for addition to ES cell differentiation regimes. S C 2011;29:629-640 [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
16. Influencing Hematopoietic Differentiation of Mouse Embryonic Stem Cells using Soluble Heparin and Heparan Sulfate Saccharides.
- Author
-
Holley, Rebecca J., Pickford, Claire E., Rushton, Graham, Lacaud, Georges, Gallagher, John T., Kouskoff, Valerie, and Merry, Catherine L. R.
- Subjects
- *
HEMATOPOIETIC stem cells , *EMBRYONIC stem cells , *CELL differentiation , *GENE expression , *PROTEIN-protein interactions , *HEPARIN , *GROWTH factors - Abstract
Heparan sulfate proteoglycans (HSPG) encompass some of the most abundant macromolecules on the surface of almost every cell type. Heparan sulfate (HS) chains provide a key interaction surface for the binding of numerous proteins such as growth factors and morphogens, helping to define the ability of a cell to respond selectively to environmental cues. The specificity of HS-protein interactions are governed predominantly by the order and positioning of sulfate groups, with distinct cell types expressing unique sets of HS epitopes. Embryos deficient in HS-synthesis (Ext1-/-) exhibit pre-gastrulation lethality and lack recognizable organized mesoderm and extraembryonic tissues. Here we demonstrate that embryonic stem cells (ESCs) derived from Ext1-/- embryos are unable to differentiate into hematopoietic lineages, instead retaining ESC marker expression throughout embryoid body (EB) culture. However hematopoietic differentiation can be restored by the addition of soluble heparin. Consistent with specific size and composition requirements for HS:growth factor signaling, chains measuring at least 12 saccharides were required for partial rescue of hematopoiesis with longer chains (18 saccharides or more) required for complete rescue. Critically N- and 6-O-sulfate groups were essential for rescue. Heparin addition restored the activity of multiple signaling pathways including bone morphogenic protein (BMP) with activation of phospho-SMADs re-established by the addition of heparin. Heparin addition to wild-type cultures also altered the outcome of differentiation, promoting hematopoiesis at low concentrations, yet inhibiting blood formation at high concentrations. Thus altering the levels of HS and HS sulfation within differentiating ESC cultures provides an attractive and accessible mechanism for influencing cell fate. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
17. Whole body correction of severe mucopolysaccharidosis type II by lentiviral-mediated stem cell gene therapy with blood-brain barrier-crossing peptides.
- Author
-
Gleitz, Hélène F.E., O'Leary, Claire, Holley, Rebecca J., and Bigger, Brian W.
- Subjects
- *
MUCOPOLYSACCHARIDOSIS II , *STEM cell treatment , *GENE therapy , *BLOOD-brain barrier , *PEPTIDES , *WHOLE body imaging , *THERAPEUTICS - Published
- 2017
- Full Text
- View/download PDF
18. Immobilization of Heparan Sulfate on Electrospun Meshes to Support Embryonic Stem Cell Culture and Differentiation.
- Author
-
Meade, Kate A., White, Kathryn J., Pickford, Claire E., Holley, Rebecca J., Marson, Andrew, Tillotson, Donna, Van Kuppevelt, Toin H., Whittle, Jason D., Day, Anthony J., and Merry, Catherine L. R.
- Subjects
- *
HEPARAN sulfate , *EMBRYONIC stem cells , *STEM cell culture , *PLURIPOTENT stem cells , *GLYCOSAMINOGLYCANS - Abstract
As our understanding of what guides the behavior of multi- and pluripotent stem cells deepens, so too does our ability to utilize certain cues to manipulate their behavior and maximize their therapeutic potential. Engineered, biologically functionalized materials have the capacity to influence stem cell behavior through a powerful combination of biological, mechanical, and topographical cues. Here,wepresent the development of a novel electrospun scaffold, functionalized with glycosaminoglycans (GAGs) ionically immobilized onto the fiber surface. BoundGAGsretained the ability to interact with GAG-binding molecules and, crucially, presented GAG sulfation motifs fundamental to mediating stem cell behavior.BoundGAGproved to be biologically active, rescuing the neural differentiation capacity of heparan sulfate-deficient mouse embryonicstemcellsandfunctioning in concert withFGF4to facilitate the formation of extensive neural processes across the scaffold surface. The combination of GAGs with electrospun scaffolds creates a biomaterial with potent applicability for the propagation and effective differentiation of pluripotent stem cells. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
19. Hematopoietic Stem Cell and Gene Therapy Corrects Primary Neuropathology and Behavior in Mucopolysaccharidosis IIIA Mice.
- Author
-
Langford-Smith, Alexander, Wilkinson, Fiona L, Langford-Smith, Kia J, Holley, Rebecca J, Sergijenko, Ana, Howe, Steven J, Bennett, William R, Jones, Simon A, Wraith, JE, Merry, Catherine LR, Wynn, Robert F, and Bigger, Brian W
- Subjects
- *
HEMATOPOIETIC stem cells , *GENE therapy , *MUCOPOLYSACCHARIDOSIS , *LABORATORY mice , *HEPARAN sulfate , *JUVENILE diseases , *GANGLIOSIDES - Abstract
Mucopolysaccharidosis IIIA (MPS IIIA or Sanfilippo disease) is a neurodegenerative disorder caused by a deficiency in the lysosomal enzyme sulfamidase (SGSH), catabolizing heparan sulfate (HS). Affected children present with severe behavioral abnormalities, sleep disturbances, and progressive neurodegeneration, leading to death in their second decade. MPS I, a similar neurodegenerative disease accumulating HS, is treated successfully with hematopoietic stem cell transplantation (HSCT) but this treatment is ineffectual for MPS IIIA. We compared HSCT in MPS IIIA mice using wild-type donor cells transduced ex vivo with lentiviral vector-expressing SGSH (LV-WT-HSCT) versus wild-type donor cell transplant (WT-HSCT) or lentiviral-SGSH transduced MPS IIIA cells (LV-IIIA-HSCT). LV-WT-HSCT results in 10% of normal brain enzyme activity, near normalization of brain HS and GM2 gangliosides, significant improvements in neuroinflammation and behavioral correction. Both WT-HSCT and LV-IIIA-HSCT mediated improvements in GM2 gangliosides and neuroinflammation but were less effective at reducing HS or in ameliorating abnormal HS sulfation and had no significant effect on behavior. This suggests that HS may have a more significant role in neuropathology than neuroinflammation or GM2 gangliosides. These data provide compelling evidence for the efficacy of gene therapy in conjunction with WT-HSCT for neurological correction of MPS IIIA where conventional transplant is ineffectual. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.